Close menu

June 30th, 2021 | 12:59 CEST

CureVac, Cardiol Therapeutics, MorphoSys - Here it is going powerfully upwards!

  • Biotechnology
Photo credits:

Biotech stocks offer investors not only an exciting but also a very profitable investment environment. But the sector is also attractive for traders due to its high volatility. CureVac took a beating recently as the efficacy of its Corona vaccine disappointed. The price of MorphoSys falls despite good news and positive analyst comments. The Canadian Cardiol Therapeutics could be on the verge of a revaluation. Where can the most significant gains be made in the short term?

time to read: 3 minutes | Author: Carsten Mainitz
ISIN: CUREVAC N.V. O.N. | NL0015436031 , CARDIOL THERAPEUTICS | CA14161Y2006 , MORPHOSYS AG O.N. | DE0006632003

Table of contents:

    CUREVAC NV - The countdown is on

    In mid-June, German biotech Company CureVac provided information on its first-generation Corona vaccine candidate, announcing that a preliminary evaluation showed the compound had an efficacy of around 47%. This announcement hit like a bomb. As a result, the share price fell by half. In the meantime, the shares have recovered somewhat to around EUR 54.

    The sharp drop was due to the significantly lower efficacy of the vaccine compared to competitors' preparations. In addition, the vaccine has not yet been approved. Astra Zeneca, BioNTech/Pfizer, Moderna and Johnson & Johnson are currently dividing the cake among themselves. Those who are too late may only have a few crumbs left.

    Now the CEO of the Tübingen-based vaccine developer CureVac, Franz-Werner Haas, has spoken out. Haas expects final results from the pivotal study phase very soon. "It won't take more than a week or ten days. We expect the results in the short term," Haas said Monday at a press conference. Like BioNTech and Moderna, CureVac relies on mRNA technology. However, the Tübingen-based Company is pursuing a slightly different approach. Haas remained convinced that the vaccine could be approved. Amsterdam's European Medicines Agency (EMA) initiated a rapid review process for the Tübingen-based Company's vaccine in February. The federal government also has a vested interest in the South German Company's success for two reasons. First, because the vaccine is firmly scheduled for a later vaccination campaign, and second, the federal government has invested EUR 300 million in CureVac through Aufbaubank KfW and holds a 16% stake.

    CARDIOL THERAPEUTICS INC - When will the revaluation start?

    Cardiol Therapeutics is breaking new ground in inflammatory heart disease therapy. The Canadians are relying on cannabidiol (CBD) for therapeutic trials. A body of scientific evidence exists that suggests the use of cannabidiol as an anti-inflammatory agent is beneficial. The Company has an exclusive manufacturing agreement for a pharmaceutical cannabidiol formulation that is highly concentrated and THC-free. In April, Cardiol enrolled the first patients in LANCER for a Phase II/III outcomes study in high-risk patients treated with Covid-19. The single and multiple ascending dose Phase I clinical trial showed successful topline results for CardiolRx in April. The Company filed for listing on NASDAQ in March 2021. Trading on the NASDAQ is expected to result in a significant valuation boost for the stock.

    Characteristically, companies like Cardiol operate at a loss in the early stages. The potential of the existing product pipeline and the management team's expertise enabled the Company to raise more than CAD 50 million on the capital market in the last 12 months. That is a considerable house number. The analysts of GBC certify the Company in the case of success, enormous profits, and formulate a price target of CAD 15.77 - a potential fivefold! In addition, the analysts classify the Company as a takeover target in case of positive results of the Covid-19 phase II/III trials. Currently, the shares are trading around CAD 3, giving the Company a market capitalization of CAD 127 million.

    MORPHOSYS AG - Now?!

    In recent months, the MorphoSys share has only known reverse gear. While the shares were still quoted at EUR 120 last summer, only EUR 68 per share is called up. The Company is thus valued at EUR 2.2 billion. The acquisition of NASDAQ-listed Constellation Pharmaceuticals Inc. for USD 34 per share in cash, announced in June, failed to give the share price any positive impetus. Analysts see clear upside potential for the German stock, but that is not helping at the moment. Perhaps a cancer drug that the US pharmaceutical Company Incyte is marketing together with MorphoSys will soon revive the share price. Incyte has concrete hopes of obtaining approval for its blood cancer drug tafasitamab in Europe. As reported last Friday, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive recommendation for the drug. If marketing is then made possible in the next step, this should be reflected in rising share prices.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.

    Der Autor

    Carsten Mainitz

    The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.

    About the author

    Related comments:

    Commented by Juliane Zielonka on June 1st, 2023 | 09:30 CEST

    BioNxt Solutions, Bayer, Palantir - AI is dominating the market at breathtaking speed and ensuring high returns

    • Biotechnology
    • Pharma
    • AI

    Tech investors have suffered heavy losses over the past year. But tech in pharma and security in defence enables entirely new future scenarios whose precise developments are worth examining more closely. For example, gentler and more effective new ways that benefit patients are emerging in the drug delivery market. At the forefront is the Company BioNxt Solutions, which specializes in innovative transdermal patches whose active ingredients literally go under the skin. In Germany, the biotech company cooperates with a German pharmaceutical partner. New times are now dawning for Bayer as well. Under the new reign of CEO Bill Anderson, digital health seems to have finally found its positioning in the Consumer Health division. There, the Company is to cooperate with exciting start-ups that collect and analyze consumer data. When it comes to networking and interpreting data using AI, one company in particular stands out at the moment. Palantir is moving out to "dominate the entire market." How? Find out in the comments below.


    Commented by Fabian Lorenz on June 1st, 2023 | 08:45 CEST

    JinkoSolar, BioNTech and First Phosphate with important updates: This is what moves the shares

    • Mining
    • phosphate
    • photovoltaics
    • Biotechnology

    The energy transition is moving forward. In Germany, the traffic light government seems to have agreed on a new heating law. In the US, the agreement between Democrats and Republicans on the debt ceiling is a good sign for the industry because the promotion of environmentally friendly technologies depends on it. JinkoSolar and First Phosphate, among others, should benefit from this. Both companies have published important updates. There is also important news at BioNTech. However, these are not so positive. When will there be new impulses for the share?


    Commented by André Will-Laudien on May 31st, 2023 | 08:30 CEST

    Biotech in turnaround mode! BioNTech, Defence Therapeutics, MorphoSys, Formycon - Take a close look at these shares!

    • Biotechnology
    • Pharma
    • vaccine

    Since the major pandemic wave in the biotech sector, most industry players have had to come to terms with normality again. Scolded investors quickly learned their lesson and are now looking warily at an industry that experienced its heyday between 2019 and 2021. Today, it is no longer the small announcements of hope that lead to significant price swings. After months of sell-offs, however, the sector is stabilizing for the first time, and some protagonists can report minor progress. When the sector trend weakens, selection is the trump card. Here are some suggestions.